A Phase I Trial of Dinaciclib (SCH727965) and MK-2206 in Metastatic Pancreatic Cancer With an Expansion Cohort in Advanced Pancreatic Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Sep 2016
At a glance
- Drugs Dinaciclib (Primary) ; MK 2206 (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 03 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jan 2017.